ReviewExpert opinion on drug safety2015
Safety of human papillomavirus vaccines: a review.
Review in Expert opinion on drug safety, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03549273 (Evaluation of the Effect of the Combination of the Natural Products Glizigen® and Ocoxin®-Viusid® in the Treatment of High-grade Cervical Intraepithelial Lesions. Phase II), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Effect of the Combination of the Natural Products Glizigen® and Ocoxin®-Viusid® in the Treatment of High-grade Cervical Intraepithelial Lesions. Phase II
Who cites it
38 citing papers in PubMed, 75 citations in OpenAlex.
- Online Decision Support for Implementing Evidence-Based HPV Vaccination Strategies in Texas Safety-Net Pediatric Clinics: Impact on HPV, MCV, and Tdap Initiation.Healthcare (Basel, Switzerland) · 2026Article
- Knowledge, Awareness and Vaccination Attitude Towards HPV in Sex and Gender Minorities: A Cross-Sectional Study.Vaccines · 2025Article
- HPV-Related Cancers in Bosnia and Herzegovina: A Comprehensive Review.Acta medica academica · 2024Review
- Vaccine hesitancy and equity: lessons learned from the past and how they affect the COVID-19 countermeasure in Indonesia.Globalization and health · 2024Review
- Article
- Safety of 4-valent human papillomavirus vaccine in males: a large observational post-marketing study.Human vaccines & immunotherapeutics · 2022Article
- Real-Life Safety Profile of the 9-Valent HPV Vaccine Based on Data from the Puglia Region of Southern Italy.Vaccines · 2022Article
- RETRACTED: COVID-19 Vaccine Hesitancy and Resistance in India Explored through a Population-Based Longitudinal Survey.Vaccines · 2021Article
- Plant-Derived Natural Compounds in Genetic Vaccination and Therapy for HPV-Associated Cancers.Cancers · 2020Review
- Post-approval Safety Monitoring of Quadrivalent and Bivalent Human Papillomavirus Vaccines Based on Real-world Data from the Korea Adverse Events Reporting System (KAERS).Clinical drug investigation · 2020Article
- Human papillomavirus (HPV) vaccine status and knowledge of students at a university in rural Thailand.Heliyon · 2020Article
- Scientific Evaluation of the Court Evidence Submitted to the 2019 Human Papillomavirus Vaccine Libel Case and Its Decision in Japan.Frontiers in medicine · 2020Article
- HPV knowledge and vaccine acceptance among European adolescents and their parents: a systematic literature review.Public health reviews · 2020Review
- Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.International journal of clinical pharmacy · 2019Article
- Post Marketing Surveillance Study of 2nd Dose Quadrivalent Human Papilloma Virus Vaccine in Elementary School Children in Jakarta, Indonesia: Safety Result and Implementation of School-Based HPV Immunization ProgramAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Medicine and the media: the ethics of virtual medical encounters.Clinical medicine (London, England) · 2019Article
- What is the most useful tool in HPV vaccine promotion? Results from an experimental study.Human vaccines & immunotherapeutics · 2019Article
- Achieving high HPV vaccine completion rates in a pediatric clinic population.Human vaccines & immunotherapeutics · 2019Article
- Safety of bivalent human papillomavirus vaccine in the US vaccine adverse event reporting system (VAERS), 2009-2017.British journal of clinical pharmacology · 2018Article
- Simultaneous Bilateral Optic Neuritis Following Human Papillomavirus Vaccination in a Young Child.Cureus · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBetween 2006 and 2009, two different human papillomavirus virus (HPV) vaccines were licensed for use: a quadrivalent (qHPVv) and a bivalent (bHPVv) vaccine. Since 2008, HPV vaccination programmes have been implemented in the majority of the industrialized countries. Since 2013, HPV vaccination has been part of the national programs of 66 countries including almost all countries in North America and Western Europe. Despite all the efforts made by individual countries, coverage rates are lower than expected. Vaccine safety represents one of the main concerns associated with the lack of acceptance of HPV vaccination both in the European Union/European Economic Area and elsewhere. AREAS COVERED: Safety data published on bivalent and quadrivalent HPV vaccines, both in pre-licensure and post-licensure phase, are reviewed. EXPERT OPINION: Based on the latest scientific evidence, both HPV vaccines seem to be safe. Nevertheless, public concern and rumors about adverse events (AE) represent an important barrier to overcome in order to increase vaccine coverage. Passive surveillance of AEs is an important tool for detecting safety signals, but it should be complemented by activities aimed at assessing the real cause of all suspect AEs. Improved vaccine safety surveillance is the first step for effective communication based on scientific evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.